The association between alkylating agent exposure and acute nonlymphocytic leukemia in humans indicates that myeloid cells may be particularly susceptible to mutagenic damage. Alkylating agent mutagenesis is frequently mediated through formation and persistence of a particular DNA base adduct, O6alkylguanine, which preferentially mispairs with thymine rather than cytosine, leading to point mutations. O6alkylguanine is repaired by O6alkylguanine-DNA alkyltransferase (alkyltransferase), a protein that removes the adduct, leaving an intact guanine base in DNA. We measured alkyltransferase activity in myeloid precursors and compared it with levels in other cells and tissues.
Introduction
There is a very strong association in humans between alkylating agent exposure and subsequent development of acute nonlymphocytic leukemia (ANLL)' (1) (2) (3) . Although initially described in patients receiving combination chemotherapy and radiation therapy for Hodgkins disease (4), ANLL has now been reported to follow the use of alkylating agents as therapy for a variety of malignant and nonmalignant conditions (5) (6) (7) (8) . The cumulative incidence of ANLL in patients with alkylating agent exposure who survive 5 yr is as high as 17% (5, 8) . While considerable efforts have been devoted to epidemiologic documentation of alkylating agent-induced ANLL, there has been little work focused on the apparent sensitivity of myeloid precursors to alkylating agent-induced mutagenesis. In this paper, we have evaluated the capacity of myeloid cells to repair DNA damage induced by alkylating agents and have compared it with the capacity present in other human tissues. Understanding the response of myeloid cells to alkylating agent mutagenic damage will help unravel the process of chemical leukemogenesis.
Alkylating agents cause damage to DNA by formation of DNA base adducts (9, 10) which, in the case of bifunctional agents, results in DNA cross-links (9-1 1). Secondary damage is induced by DNA protein cross-links (1 1, 12) and by repair processes that can result in base substitution, strand breaks, and rearrangements ( 13) . Cytotoxicity results from sufficient alkylation of DNA and proteins to disrupt cellular metabolism and replication (14) . Mutagenesis and carcinogenesis, on the other hand, occur in less severely affected cells that retain their ability to replicate but are unable to completely repair point mutations, deletions, rearrangements, or translocations (13).
14 major sites of DNA adduct formation have been described for the alkylating agents (15) . Most of these adducts are not directly mutagenic (15, 16) . In contrast, the O6alkylguanine adduct is highly mutagenic because the altered base preferentially mispairs with thymine rather than undergoing the normal base pairing of guanine with cytosine (17). In subsequent rounds of replication, this mispairing results in propagation of a point mutation in which an adenine-thymine base pair is substituted for a guanine-cytosine base pair (15, 16 (18) and carcinogenesis in rat brain (19) , kidney, liver (20, 21) , and thymus (22, 23) . In addition, this type of guanine to adenine point mutation has been found to be the single change responsible for activation of the H-ras oncogene present in the methylnitrosourea (MNU)-induced rat mammary carcinoma (24) . Because O6methylguanine (MG) is an adduct formed by MNU (10, 15, 22) , it appears that this adduct is likely to be responsible for oncogene activation in this particular rat mammary carcinoma.
DNA alkyl-adduct repair proceeds by three basic mechanisms. Some adducts, such as N7alkylguanine and N3alkyl-adenine, are removed by specific DNA-glycosylases (13, 25) . The DNA strand is then cleaved at the apurinic site by the action of an apurinic endonuclease. Larger adducts are removed by nucleases that excise the abnormal and adjacent bases (13) . In both instances the correct nucleotides are inserted into DNA by DNA polymerase and the strand break closed with DNA ligase by a protein called O6alkylguanine-DNA alkyltransferase, which transfers the alkyl group from the O6 of guanine to a cysteine moiety in the protein, leaving an intact guanine molecule in the DNA (26, 27) .
The O6alkylguanine-DNA alkyltransferase (alkyltransferase) has been described in both prokaryotes and eukaryotes (26) (27) (28) (29) . The protein has a molecular weight of 18,000-26,000 (26, 28) . It acts in a stoichiometric fashion, in which each protein molecule is capable of transferring one alkyl group from O6alkylguanine to the protein with a t112 of between 15 and 47 min (28, 29) .
Once the alkyl group is covalently transferred to a cysteine residue in the protein, the protein becomes permanently inactivated and activity is not regenerated in the absence of protein synthesis (30) . Consequently, alkylating agents that cause a large number of O6alkylguanine adducts can saturate the cellular content of O6alkylguanine-DNA alkyltransferase, producing a threshold effect in the number of persistent O6alkylguanine lesions and point mutations (18) in cells undergoing DNA replication.
A cell's susceptibility to the mutagenic effects of alkylating agents depends, in part, on the relative amount of O6alkylguanine-DNA alkyltransferase. Previous studies have shown that human liver contains the highest level of activity (27) , with lower levels seen in stomach (31) , small intestine, colon (32, 33) , and brain (34) . All fresh human tissues analyzed contain alkyltransferase, whereas studies with human cell lines have identified some that lack the enzyme (35) . There have been no studies on the level of the alkyltransferase in human bone marrow cells or myeloid precursors.
This study was conducted to determine the range of activity of O6alkylguanine-DNA alkyltransferase in myeloid precursors and to compare this range with that found in other tissues. We hypothesized that ifthe activity were found to be low in myeloid precursors, it could provide a rationale for the susceptibility of myeloid cells to alkylating agent-induced transformation.
Methods
Cell line. The HL-60 promyelocytic cell line (36) was obtained from the American type culture collection (Camden, NJ). The cell line was maintained in exponential growth phase by biweekly passage in culture medium consisting of RPMI-1640 (Gibco, Grand Island, NY) supplemented with 15% fetal calf serum (Sterile Systems, Logan, UT), 100 U/ml penicillin-streptomycin solution (Gibco), 2 mM glutamine, and 25 mM Hepes (Sigma Chemical Co., St. Louis, MO).
Peripheral blood and bone marrow fractionation. After informed consent, 150 ml of blood was drawn from healthy donors into plastic syringes. Blood was anticoagulated with heparin or was defibrinated in the presence of50 ml 5% dextran in order to remove platelets as previously described (37) . Preparation ofcells by either method gave similar results. Defibrinated blood was sedimented for I h at unit gravity, 37°C, and the buffy coat-rich plasma-dextran upper layer collected. The defibrinated buffy coat or heparinized whole blood was layered over Ficoll-Hypaque (specific gravity = 1.077, Sigma Chemical Co.) and separated by density gradient centrifugation at 1,000 g X 30 min at 22°C as previously described (38) . Granulocytes in the pellet were isolated after osmotic shock lysis of the erythrocytes by incubation at 4°C for 3 min in 4 vol of lysing buffer consisting of 0.155 M NH4Cl, 0.015 M NH4HCO3, and 0.1 mM EDTA followed by dilution into phosphate-buffered saline (PBS) (37) and centrifugation at 500 g X 10 min. Low density mononuclear cells were recovered at the Ficoll-Hypaque interface. Monocytes were isolated by adherence during a 90-min incubation in RPMI-1640 culture medium at 1 X 106 cells/ml in 75-cm2 tissue culture flasks (Costar, Cambridge, MA) preincubated for 90 min with heat inactivated, pooled human A/ B serum, using published methods (38, 39) . After the nonadherent cells were removed, the adherent monocytes were washed twice with 10 ml PBS, exposed to 20 ml PBS-I mM EDTA for 20 min at 40C, and collected by sweeping the flask with a rubber policeman.
The nonadherent, mononuclear cells were further separated into T and B lymphocyte fractions using the capacity of T cells to form rosettes with neuraminidase (Sigma Chemical Co.) treated sheep erythrocytes (Wilfer Laboratories, Stillwater, MN) during a 90-min incubation at 40C as previously described (40) .
Bone marrow was obtained either from healthy donors, after informed consent, or from individuals with normal bone marrows undergoing bone marrow harvest for bone marrow transplantation. 8 ml of bone marrow were aspirated from the posterior iliac crest into a syringe containing 250 U heparin as previously described (38, 41) . The bone marrow was fractionated using methods similar to that described above for peripheral blood. Briefly, granulocytes, bands, and metamyelocytes were recovered in the pellet of the Ficoll-Hypaque gradient. Adherent cells were recovered as described above and consisted of monocytes with 1-5% fibroblasts. The buffer and frozen at -20°C. Cell extracts were prepared by sonication three times for 5 s at 4°C to complete cell disruption using a microsonicator equipped with a 3/32-in. diameter probe (Kontes Glass Co., Vineland, NJ) followed by centrifugation at 10,000 g X 2 min to remove cellular debris (43, 44) . Tissue samples were homogenized in a Ten Broeck cell disrupter (Fisher Scientific Co., Pittsburgh, PA) and then sonicated and centrifuged as described above. Cell extract supernatant was collected and the protein concentration determined by the method of Bradford (45) . The DNA concentration was determined fluorometrically using Hoescht dye 33258 (Calbiochem-Behring Corp., La Jolla, CA) and calf thymus DNA (type 5, Sigma Chemical Co.) as standard (46) . Enzyme activity in cell extracts was stable for 2 wk when stored at -20°C, but underwent a 20% loss in activity over a 3-mo period.
O6Alkylguanine-DNA alkyltransferase assay. (27, 32, 44 45 min, which removed >95% of the [3H]methyl purines. The hydrolysate was neutralized by addition of 400 ,ul 0.02 M Tris base, pH 10.6. The supernatant was collected after centrifugation at 10,000 g X 2 min and combined with a 200-,ul distilled water wash of the residual pellet. Large molecular weight fragments (>2,000 mol wt) were removed from the supernatant by filtration through a low binding affinity TM membrane in a Centrifree apparatus (Amicon Corp., Lexington, MA).
The methyl purines in the sample were separated by high performance liquid chromatography (HPLC) using a 5000 liquid chromatograph equipped with a 1.0-ml loop, an internal UV-100 detector, and an MCH- 5 Chromatographic analysis ofS-methylcysteine formation. To determine whether [3H~methyl moieties lost from [3H]MG during the reaction incubation were transferred to protein, we digested the reaction mixture with proteases and performed an amino acid analysis using a modification of a previously described method (26, 30) . Briefly, after collection of the TCA precipitate formed in the reaction mixture described above, the pellet was washed twice in 100% ethanol at 4°C and air dried. The pellet was redissolved in 0.2 ml of 75 mM Hepes, pH 7.8, 1 mM EDTA, and 1 mM dithiothreitol buffer and digested with 60 ,ug proteinase K fQr 12 h at 37°C and with 1 U microsomal leucine Aminopeptidase (Sigma Chemical Co.) for 4 h. The remaining large molecular weight molecules were precipitated with 0.5 ml 100% ethanol at -20°C for I h and the supernatant collected after centrifugation at 10,000 g X 2 min. The ethanol was allowed to evaporate and the remaining solution spotted onto 3-M chromatography paper (Whatman Ltd., London, England), which was subjected to descending chromatography in a humidified chamber for 20 h using a solvent of ethanol, butanol, and water (2:2:1), as previously described (26) . Amino acid standards run at the same time were S-methylcysteine, cysteine, serine, glycine, and methionine (Sigma Chemical Co). The chromatograph was developed with ninhydrin, cut into ½/2-in. strips, solubilized overnight in 0.05 ml water and 0.5 ml Protosol tissue solubilizer (New England Nuclear, Boston, MA), dissolved in scintillation fluid (48) , and the radioactivity determined by scintillation counting.
Results
Characterization ofO6alkylguanine-DNA alkyltransferase in the myeloid cell line HL-60. To determine whether O6alkylguanine-DNA alkyltransferase existed in myeloid cells and if its characteristics were similar to those described for other cell types, we assayed for removal of [3H]O6MG by cell extracts of the myeloid cell line, HL-60. Fig. I presents the time course of the removal of O6MG residues in methyl DNA by the alkyltransferase present in HL-60 cell extract. Removal of methyl adducts from O6MG is essentially complete in <30 min at concentrations of cell extract of both 250 and 500 ,Ig protein. We therefore selected 60 min for subsequent reactions to ensure sufficient time for the reaction to go to completion. Using this incubation period, we found that removal of O6MG by extracts of HL-60 is linearly dependent on the amount ofcell extract added between 25 and 500 ug protein of cell extract.
We next evaluated the location of the methyl moieties lost from O6MG during the reaction with HL-60 extract, to determine whether they became protein bound. This is the reported mechanism by which O6alkylguanine-DNA alkyltransferase acts in other cells (27, 28) . The alkyltransferase reaction mixture was subject to protease digestion and the amino acids separated by paper chromatography. As can be seen in Fig. 2 , the radioactivity has become transferred to S-methylcysteine residues. The amount of radioactivity present in the [3H]methylcysteine peak was, within experimental error, the same as that lost from the [3H]O6MG peak recovered by HPLC. Thus, myeloid cells removed the methyl adduct from O6MG in DNA by transfer of the methyl group from O6MG onto a cysteine residue in proteins in a rapid, stoichiometric fashion, which was linearly dependent on the amount of alkyltransferase present in the reaction.
O6Alkylguanine-DNA alkyltransferase in peripheral blood cells. To determine whether normal nucleated blood cells contained alkyltransferase and to determine the differences in alkyltransferase activity that occurred in different cell lineages and transferase activity. To do this analysis, we compared individuals Lnge of 06alkylguanine-DNA alkyltransferase activity from whom we had assayed both T lymphocytes and myeloid )lood cells is shown in Fig. 3 . There was a 4-6-fold precursors. These individuals are identified by the solid lines range of activity among the 7-20 donors shown for each cell type. The mean value for alkyltransferase activity in each cell type ranged from 99±39 fmol O6MG/mg protein (mean±SD) in granulocytes to 189±60 fmol O6MG/mg protein in T lym- Figure 3 . 06alkylguanine-DNA alkyltransferase activity in isolated peripheral blood nucleated cells. Nucleated white blood cells were separated into granulocytes, monocytes, and T and B lymphocytes. Extracts were prepared and assayed for alkyltransferase as described in the text. Cells were prepared from 20 donors. Samples in which insufficient cells of a particular type were obtained or in which the purity of the preparation was poor were excluded from analysis. The mean level of alkyltransferase present in each cell type is indicated by the larger circle to the left of the column of points. Fig. 4 . In 18 of these 19 donors, the myeloid precursors had lower or equal alkyltransferase activity than the T lymphocytes, and in 13, the myeloid precursors were actually lower (P < 0.05, paired t test, two sided). In only one individual was the alkyltransferase activity markedly higher in the myeloid precursors than the T lymphocytes. In addition, in these 19 donors there was a significant correlation between the alkyltransferase level found in T lymphocytes and the activity found in myeloid precursors (r = 0.69, P < 0.005). These results indicate that despite the wide range of alkyltransferase activity observed between individuals, the activity is usually higher in T lymphocytes than myeloid precursors in the same individual. In Figs. 5 and 6 show the O6alkylguanine-DNA alkyltransferase activity in various tissues compared with myeloid precursors and T lymphocytes. On the basis of cell protein content (Fig.  5) , only a fourfold variation in mean alkyltransferase activity is observed between tissues. However, comparing the alkyltransferase activity between tissues on the basis of DNA content (Fig.  6) , there is a 15-fold range in activity. In each tissue, there is a 3-6-fold range of activity between individuals. Based on a relative mean alkyltransferase activity in human liver of 100%, the relative alkyltransferase activity in small intestine was 35%, in colon was 14%, in T lymphocytes and brain was 11%, and in myeloid precursors only 6.6% (Table I ). The highest levels observed in T lymphocytes and myeloid precursors are less than the lowest values observed with liver or small intestine. Thus, on the basis of O6alkylguanine-DNA alkyltransferase per microgram cellular DNA, normal myeloid precursors contain the lowest levels of activity of the tissues tested. These studies suggest that myeloid precursors are a likely target for mutagenic DNA damage by alkylating agents and that, in these cells, the level of alkyltransferase activity varies greatly between individuals.
Before it is reasonable to interpret the significance of low levels of alkyltransferase in terms of mutagenic risk, it is important to determine how stable the alkyltransferase level is over time in the same individual. Since we noted a good correlation between T lymphocytes and myeloid precursors, we tested lymphocytes from seven individuals on more than one occasion and found similar alkyltransferase levels on each occasion. In addition, two individuals were tested over a 4-wk period (Fig. 7) . As can be seen, the two individuals maintained a similar level for alkyltransferase activity (22, 23) , the second is the capacity for repair (26) (27) (28) , and the third is the proliferative state of the cell after formation of the adduct (20) . The first two factors control the number and persistence ofadducts, while the third factor controls the rate at which the adduct is converted into a point mutation during DNA replication (15, 16, 52 (24) . This study is the first to demonstrate the presence of alkyltransferase activity in human myeloid precursors and to compare its activity with a number of other human tissues. Other investigators (27, (29) (30) (31) (32) (33) (34) have found mean levels of alkyltransferase based on cellular protein content that agree quite closely with levels we observed for liver, small intestine, colon, and brain (27, (32) (33) (34) . According to the published data for stomach and kidney (32, 34) , both tissues appear to contain more alkyltransferase activity than we found in myeloid precursors. We base this conclusion on the published values of alkyltransferase activity per milligram cellular protein, because determinations of alkyltransferase activity per microgram cellular DNA have not been done. As mentioned above, we feel that alkyltransferase activity based on cellular DNA content is a more accurate way to express relative activity between tissues because of the variation between tissues in cellular protein content. Consequently, it remains possible that the alkyltransferase activity per microgram DNA in stomach and kidney is lower than that in brain and myeloid precursors.
Nonetheless, of the organs tested to date, those with the highest relative risk for mutagenic damage appear to be myeloid precursors, brain, and lymphocytes. In mammalian species, the brain is a target for carcinogenic damage by alkylating agents (19) , but there is no association of brain tumors with alkylating agent exposure in humans. The reason for this in humans is unclear, but may have to do with the proliferative activity of glial cells in adult human brain, the existence of the blood-brain barrier, and the lag time necessary between exposure and onset of a detectable tumor. Colon epithelium, on the other hand, does undergo proliferation, and the relatively low levels of alkyltransferase activity in this tissue could contribute to the high level of colon carcinoma.
Cell proliferation is the third factor contributing to mutagenic damage by alkylating agents. In the bone marrow, alkylating agents cause a significant destruction of myeloid precursors (53) , and, as a consequence, the release of stimulating factors for hematopoiesis (54) . These factors induce intense cell proliferation 2-5 d after alkylating agent exposure (53) , allowing mutations to be efficiently locked into the genome of myeloid cells. Re06Alkylguanine-DNA Alkyltransferase Activity 2111 peated exposure to alkylating agents during this period of active DNA synthesis would be particularly mutagenic to hematopoietic stem cells recruited into cell cycle. The end result would be clonal growth of myeloid cells containing a large number of point mutations.
In contrast, lymphocytes protect themselves from alkylating agent-induced DNA damage. First, lymphocytes do not, in the absence of an antigenic stimulus, undergo a strong proliferative burst after alkylating agent exposure, so that the cells have time to repair DNA damage before replication. Second, lymphocytes increase their 06alkylguanine-DNA alkyltransferase levels after mitogen stimulation (44) , thereby repairing adducts during DNA replication. This may explain why lymphoma or lymphoid leukemia are infrequently observed in humans after alkylating agent exposure (1) (2) (3) (4) (5) (6) (7) (8) .
The second important observation of this paper is that individuals vary greatly in the level of alkyltransferase activity found in their myeloid precursors, and that this level appears to be maintained over time. Others have found a similar wide range in interindividual alkyltransferase activity in lymphocytes (44) , colon (32) , liver (32, 33) , intestine (32) , stomach (32, 33) , and brain (34) . However, these earlier studies were not able to evaluate the stability of alkyltransferase activity in various organs over time. We observed that there was a stable level of activity within T lymphocytes over time and that there was a reasonably good correlation between the alkyltransferase activity in lymphocytes and that in myeloid precursors. We, as others (32) (33) (34) 44) , found that the 3-9-fold range of alkyltransferase activity between individuals was not dependent on age or sex of the individual. These findings suggest that certain individuals may be particularly susceptible to mutagenic damage and malignant transformation from nitrosoureas and other alkylating agents that produce the 06alkylguanine adduct. Furthermore, this susceptibility may involve more than one cell lineage.
The bone marrow also appears to be susceptible to the cytotoxic and mutagenic effects of other alkylating agents, such as the nitrogen mustard derivatives. These agents are mutagenic in the Ames assay (55) but produce much lower levels of 06alkylguanine than the nitrosoureas. The most common adduct produced by the nitrogen mustard derivatives is N7alkylguanine, which itself is not mutagenic but can form the basis of intraand interstrand cross-links (56) . These cross-links may be responsible for the observed increase in sister chromatid exchanges seen with these agents (57) . Furthermore, the susceptibility of the myeloid precursors to these agents in addition to the nitrosoureas (1) (2) (3) (4) (5) (6) (7) (8) suggests that these cells may have low levels of other DNA repair enzymes, such as those involved in excision repair, in addition to the alkyltransferase.
Because animal studies indicate that the nitrosoureas are the most potent leukemogenic alkylating agents (58) , and other studies indicate that 06alkylguanine is the critical adduct for transformation (59) , it would appear that 06alkylguanine is an important adduct involved in the induction of leukemia. However, in other systems, it has been noted that 04alkylthymine is a potent mutagenic adduct that persists in those organs that are targets for malignant transformation after alkylating agent exposure (60) . Like 06alkylguanine, this adduct is produced by the nitrosoureas, and thus may also be involved in the pathogenesis of alkylating agent-induced leukemia.
As results of cancer chemotherapy improve, more individuals enjoy a prolonged survival after alkylating agent exposure. For this reason, it may become important to identify individuals susceptible to alkylating agents before they are treated. Based on our studies, it would be appropriate to screen patients blood cells for O6alkylguanine-DNA alkyltransferase activity. Individuals with low levels of alkyltransferase might be encouraged to limit their exposure to these agents. Because of the strong correlation between myeloid precursor and T lymphocyte alkyltransferase levels within the same individual, it would be possible to screen the peripheral blood cells rather than necessitating repeated bone marrow examinations.
Finally, given that a particular tissue and particular individuals may be at risk for mutagenic damage from alkylating agents, the question arises of how to increase the endogenous alkyltransferase activity in the bone marrow of individuals with low levels of activity. Other investigators have found that exposure to alkylating agents themselves may induce the alkyltransferase protein in prokaryotes and certain mammalian tissues (20, 21, 26) . However, there are no reports of other, more benign inducing agents. The search for such agents remains an active area of investigation.
